Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Testosterone Enanthate Super-Responder Profile: Who Gets the Best Results?

By
Published Updated Last reviewed
10 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Drug / testosterone enanthate injection, Schedule III controlled substance [1]
  • Approved use / primary or hypogonadotropic hypogonadism confirmed by two morning low testosterone measurements [1]
  • Label dose / 50 to 400 mg intramuscularly every 2 to 4 weeks [1]
  • Dose-response trial / 61 healthy men; fat-free mass rose with weekly enanthate dose [2]
  • Hematocrit / intramuscular enanthate/cypionate raised mean hematocrit 4.0% versus placebo in a 29-trial analysis [3]
  • Cardiac trial / TRAVERSE tested testosterone gel, not enanthate injections [4]

Is there a real super-responder profile?

No reliable response profile has been established. The enanthate label gives a dose range and says dosage depends on age, diagnosis, response and adverse effects [1]. The 20-week dose-response trial measured dose-related changes in fat-free mass, not individual traits that predict unusually large gains [2]. Research on androgen receptor CAG repeats describes subtle differences in androgen effects, but it does not show that repeat length predicts an individual response to testosterone [6]. A study of 10 normal men found that fragmented sleep delayed the nocturnal testosterone rise; it did not test who gains more from testosterone enanthate [7].

What the dose-response trial actually shows

Bhasin et al. studied 61 eugonadal men aged 18 to 35, not men with hypogonadism, who received a GnRH agonist plus weekly testosterone enanthate 25, 50, 125, 300 or 600 mg for 20 weeks [2]. Fat-free mass increased by 3.4, 5.2 and 7.9 kg in the 125, 300 and 600 mg groups, respectively [2]. Sexual function, mood and PSA did not change significantly at any dose [2]. The trial supports dose-dependent body-composition change.

What the label says about dose and diagnosis

The intramuscular enanthate label says 50 to 400 mg every 2 to 4 weeks; total doses above 400 mg per month are not required, and injections more often than every 2 weeks are rarely indicated [1]. It also says to confirm the diagnosis with morning serum testosterone on at least two separate days, both below the normal range [1]. The Endocrine Society guideline likewise recommends diagnosing hypogonadism only in men with symptoms and signs and unequivocally and consistently low serum testosterone [5].

Which risks are higher with injectable enanthate?

A network meta-analysis of 29 placebo-controlled randomized trials in 3,393 men found that intramuscular testosterone enanthate/cypionate raised mean hematocrit by 4.0% versus placebo (95% CI 2.9 to 5.1) [3]. A retrospective review of 178 hypogonadal men found hematocrit above 50% in 66.7% of men on injectable testosterone, 12.8% on gels and 35.1% on pellets; the injection group was younger with higher baseline hematocrit, and the study was not randomized [8]. A separate review says short-acting injectable formulations have the highest incidence of erythrocytosis [9]. The enanthate label lists polycythemia, gynecomastia that may persist, and venous thromboembolism among adverse reactions, and says testosterone can increase blood pressure and is not recommended in uncontrolled hypertension [1]. The Endocrine Society guideline recommends against starting testosterone in men with elevated hematocrit, untreated severe sleep apnea, uncontrolled heart failure, or myocardial infarction or stroke within 6 months, and in men planning fertility in the near term [5].

What about heart safety and age-related low testosterone?

TRAVERSE randomized 5,246 men aged 45 to 80 with hypogonadism and preexisting or high cardiovascular risk to daily 1.62% testosterone gel or placebo; major adverse cardiovascular events occurred in 7.0% versus 7.3%, hazard ratio 0.96 (95% CI 0.78 to 1.17), meeting noninferiority [4]. The enanthate label checked still says safety and efficacy in men with age-related hypogonadism have not been established, and its cardiovascular paragraph is the older wording (long-term safety trials not conducted, studies inconclusive for major cardiovascular events) with no TRAVERSE text [1]. In June 2026 FDA asked for that limitation of use to be removed from testosterone labels [10].

Frequently asked questions

What predicts a stronger response to testosterone enanthate?
No validated predictor exists. The best-supported signal is dose: in a 20-week trial of 61 healthy men whose own testosterone was suppressed, weekly enanthate raised fat-free mass dose-dependently [2].
Is 100 to 200 mg weekly the standard enanthate dose?
The intramuscular enanthate label says 50 to 400 mg every 2 to 4 weeks, with total doses above 400 mg per month not required and injections more often than every 2 weeks rarely indicated [1].
Does injectable enanthate raise hematocrit?
In a 29-trial network meta-analysis, intramuscular enanthate/cypionate raised mean hematocrit 4.0% versus placebo [3]. A nonrandomized review found hematocrit above 50% in 66.7% of injectable users versus 12.8% on gels [8].
Did TRAVERSE test enanthate injections?
No. TRAVERSE tested daily 1.62% testosterone gel; major adverse cardiovascular events were 7.0% with testosterone and 7.3% with placebo, hazard ratio 0.96 [4].

References

  1. U.S. National Library of Medicine, DailyMed. Testosterone enanthate injection USP intramuscular, Hikma prescribing information. Testosterone enanthate injection USP intramuscular, Hikma label
  2. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172-81. Testosterone dose-response relationships in healthy young men
  3. Nackeeran S, Kohn T, Gonzalez D, White J, Ory J, Ramasamy R. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials. J Urol. 2022;207(1):44-51. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials
  4. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. Cardiovascular Safety of Testosterone-Replacement Therapy
  5. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
  6. Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl. 2003;26(2):76-83. The CAG repeat polymorphism within the androgen receptor gene and maleness
  7. Luboshitzky R, Zabari Z, Shen-Orr Z, Herer P, Lavie P. Disruption of the nocturnal testosterone rhythm by sleep fragmentation in normal men. J Clin Endocrinol Metab. 2001;86(3):1134-9. Disruption of the nocturnal testosterone rhythm by sleep fragmentation in normal men
  8. Pastuszak AW, Gomez LP, Scovell JM, Khera M, Lamb DJ, Lipshultz LI. Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen. Sex Med. 2015;3(3):165-73. Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen
  9. Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis Following Testosterone Therapy. Sex Med Rev. 2018;6(1):77-85. Erythrocytosis Following Testosterone Therapy
  10. Testosterone Information | FDA. Testosterone Information | FDA
Evidence overview for Testosterone Enanthate Super-Responder Profile: Who Gets the Best Results?